Key result
In patients with eosinophilic myocarditis, treatment with prednisolone and etiology-specific therapies improved clinical scores from 4.7 to 1.9 and yielded an 86% survival rate.
Why the study?
Does prednisolone alongside etiology-specific treatment improve survival in patients with eosinophilic myocarditis?
Observational (n=7)
No
Does prednisolone alongside etiology-specific treatment improve survival in patients with eosinophilic myocarditis?
In a small case series, administration of prednisolone alongside etiology-specific treatment was associated with a high survival rate (86%) in patients with eosinophilic myocarditis.
Answers are grounded in this paper and cite their sources.
May support prednisolone plus etiology-specific therapy in eosinophilic myocarditis; leaves open need for controlled trials before practice change.
BACKGROUND: Eosinophilic myocarditis is a rare clinical entity characterized by eosinophilia and myocardial inflammation with infiltrating eosinophils. The prognosis of patients with eosinophilic myocarditis is difficult to determine due the disease's rarity and varied causes; consequently, standard treatment has not been established. OBJECTIVE: To elucidate the clinical characteristics and treatment outcome of eosinophilic myocarditis, we retrospectively studied 7 patients fulfilling the criteria of the Japanese Circulation Society for eosinophilic myocarditis from among 64 patients admitted to our institution with eosinophilia over a 27-year period. RESULTS: The patients' ages at diagnosis ranged from 36 to 83 years (median: 52 years). The etiologies of the eosinophilic myocarditis were found to be idiopathic (3 patients), Churg-Strauss syndrome (2 patients), parasitic infection (1 patient) and chronic eosinophilic leukemia (CEL) (1 patient). In addition to treatment for the underlying disease, we also administered prednisolone at a dose appropriate to the disease severity (6 of 7 patients). The patient who was diagnosed with a parasitic infection was treated only with albendazole, because eosinophilic myocarditis was mild. The patient with CEL was positive for the FIP1 L1-PDGFRα fusion gene and was treated with imatinib. Eosinophilic cationic protein was a useful marker for assessing disease activity and treatment efficacy. At the end of the study, of the seven patients treated, six were alive (86%), giving a mean survival time of 37 ± 40 months (mean ± SD). CONCLUSION: Because eosinophilic myocarditis has various etiologies, it is essential to identify the etiology of the underlying disease. In the majority of eosinophilic myocarditis patients, administration of prednisolone may be an effective therapeutic modality producing a good outcome.
No takes yet. Share an insight, caveat, or question.
Kawano et al. (2011) conducted an observational in Eosinophilic myocarditis (n=7). Prednisolone vs. Pre-treatment baseline was evaluated on Japanese Circulation Society guideline score (p=<0.05). In patients with eosinophilic myocarditis, treatment with prednisolone and etiology-specific therapies improved clinical scores from 4.7 to 1.9 and yielded an 86% survival rate.
Synapse has enriched 10 related papers. Consider them for comparative context: